Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Fast Track Articles
  5. Fast Track Article
image of Exploration of the Role of Vitamins in Preventing Neurodegenerative Diseases: Comprehensive Review on Preclinical and Clinical Findings

Abstract

Neurodegenerative diseases (NDDs) are a multifaceted and heterogeneous group of complex diseases. Unfortunately, a cure for these conditions has yet to be found, but there are ways to reduce the risk of developing them. Studies have shown that specific vitamins regulate the brain molecules and signaling pathways, which may help prevent degeneration. This review focuses on examining the role of vitamins in preventing five significant types of neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). This review also highlights promising and controversial findings about the potential impact of vitamins on this group of diseases. Several developed countries standardize daily dietary vitamin intake to meet nutrient requirements, improve health, and prevent chronic diseases like NDDs. However, more research is necessary to gain a more comprehensive understanding of their therapeutic benefits, including studies exploring different drug-dose paradigms, diverse humanized animal models, and clinical trials conducted in various

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X327677240902105443
2024-11-21
2024-12-28

  • From This Site

    /content/journals/cn/10.2174/011570159X327677240902105443
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Shenkin A. Micronutrients in health and disease. Postgrad Med J 2006 82 971 559 67 10.1136/pgmj.2006.047670
    [Google Scholar]
  2. Lahoda Brodska H. Klempir J. Zavora J. Kohout P. The role of micronutrients in neurological disorders. Nutrients 2023 15 19 4129 10.3390/nu15194129
    [Google Scholar]
  3. Kumar R.R. Singh L. Thakur A. Singh S. Kumar B. Role of vitamins in neurodegenerative diseases: A review. CNS Neurol. Disord. Drug Targets 2022 21 9 766 773 10.2174/1871527320666211119122150 34802410
    [Google Scholar]
  4. Rai S.N. Singh P. Steinbusch H.W.M. Vamanu E. Ashraf G. Singh M.P. The role of vitamins in neurodegenerative disease: An update. Biomedicines. 2021 9 10 1284 10.3390/biomedicines9101284
    [Google Scholar]
  5. Šeper V. Nešić N. Nutrition patterns in Alzheimer’s disease 42 Southeastern. Eur. Med. J. 2019 3 1
    [Google Scholar]
  6. Nichols E. Steinmetz J.D. Vollset S.E. Fukutaki K. Chalek J. Abd-Allah F. Abdoli A. Abualhasan A. Abu-Gharbieh E. Akram T.T. Al Hamad H. Alahdab F. Alanezi F.M. Alipour V. Almustanyir S. Amu H. Ansari I. Arabloo J. Ashraf T. Astell-Burt T. Ayano G. Ayuso-Mateos J.L. Baig A.A. Barnett A. Barrow A. Baune B.T. Béjot Y. Bezabhe W.M.M. Bezabih Y.M. Bhagavathula A.S. Bhaskar S. Bhattacharyya K. Bijani A. Biswas A. Bolla S.R. Boloor A. Brayne C. Brenner H. Burkart K. Burns R.A. Cámera L.A. Cao C. Carvalho F. Castro-de-Araujo L.F.S. Catalá-López F. Cerin E. Chavan P.P. Cherbuin N. Chu D-T. Costa V.M. Couto R.A.S. Dadras O. Dai X. Dandona L. Dandona R. De la Cruz-Góngora V. Dhamnetiya D. Dias da Silva D. Diaz D. Douiri A. Edvardsson D. Ekholuenetale M. El Sayed I. El-Jaafary S.I. Eskandari K. Eskandarieh S. Esmaeilnejad S. Fares J. Faro A. Farooque U. Feigin V.L. Feng X. Fereshtehnejad S-M. Fernandes E. Ferrara P. Filip I. Fillit H. Fischer F. Gaidhane S. Galluzzo L. Ghashghaee A. Ghith N. Gialluisi A. Gilani S.A. Glavan I-R. Gnedovskaya E.V. Golechha M. Gupta R. Gupta V.B. Gupta V.K. Haider M.R. Hall B.J. Hamidi S. Hanif A. Hankey G.J. Haque S. Hartono R.K. Hasaballah A.I. Hasan M.T. Hassan A. Hay S.I. Hayat K. Hegazy M.I. Heidari G. Heidari-Soureshjani R. Herteliu C. Househ M. Hussain R. Hwang B-F. Iacoviello L. Iavicoli I. Ilesanmi O.S. Ilic I.M. Ilic M.D. Irvani S.S.N. Iso H. Iwagami M. Jabbarinejad R. Jacob L. Jain V. Jayapal S.K. Jayawardena R. Jha R.P. Jonas J.B. Joseph N. Kalani R. Kandel A. Kandel H. Karch A. Kasa A.S. Kassie G.M. Keshavarz P. Khan M.A.B. Khatib M.N. Khoja T.A.M. Khubchandani J. Kim M.S. Kim Y.J. Kisa A. Kisa S. Kivimäki M. Koroshetz W.J. Koyanagi A. Kumar G.A. Kumar M. Lak H.M. Leonardi M. Li B. Lim S.S. Liu X. Liu Y. Logroscino G. Lorkowski S. Lucchetti G. Lutzky Saute R. Magnani F.G. Malik A.A. Massano J. Mehndiratta M.M. Menezes R.G. Meretoja A. Mohajer B. Mohamed Ibrahim N. Mohammad Y. Mohammed A. Mokdad A.H. Mondello S. Moni M.A.A. Moniruzzaman M. Mossie T.B. Nagel G. Naveed M. Nayak V.C. Neupane Kandel S. Nguyen T.H. Oancea B. Otstavnov N. Otstavnov S.S. Owolabi M.O. Panda-Jonas S. Pashazadeh Kan F. Pasovic M. Patel U.K. Pathak M. Peres M.F.P. Perianayagam A. Peterson C.B. Phillips M.R. Pinheiro M. Piradov M.A. Pond C.D. Potashman M.H. Pottoo F.H. Prada S.I. Radfar A. Raggi A. Rahim F. Rahman M. Ram P. Ranasinghe P. Rawaf D.L. Rawaf S. Rezaei N. Rezapour A. Robinson S.R. Romoli M. Roshandel G. Sahathevan R. Sahebkar A. Sahraian M.A. Sathian B. Sattin D. Sawhney M. Saylan M. Schiavolin S. Seylani A. Sha F. Shaikh M.A. Shaji K.S. Shannawaz M. Shetty J.K. Shigematsu M. Shin J.I. Shiri R. Silva D.A.S. Silva J.P. Silva R. Singh J.A. Skryabin V.Y. Skryabina A.A. Smith A.E. Soshnikov S. Spurlock E.E. Stein D.J. Sun J. Tabarés-Seisdedos R. Thakur B. Timalsina B. Tovani-Palone M.R. Tran B.X. Tsegaye G.W. Valadan Tahbaz S. Valdez P.R. Venketasubramanian N. Vlassov V. Vu G.T. Vu L.G. Wang Y-P. Wimo A. Winkler A.S. Yadav L. Yahyazadeh Jabbari S.H. Yamagishi K. Yang L. Yano Y. Yonemoto N. Yu C. Yunusa I. Zadey S. Zastrozhin M.S. Zastrozhina A. Zhang Z-J. Murray C.J.L. Vos T. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the global burden of disease study 2019. Lancet Public Health 2022 7 2 e105 e125 10.1016/S2468‑2667(21)00249‑8 34998485
    [Google Scholar]
  7. Businaro R. Vauzour D. Sarris J. Münch G. Gyengesi E. Brogelli L. Zuzarte P. Therapeutic opportunities for food supplements in neurodegenerative disease and depression. Front Nutr. 2021 8 669846 10.3389/fnut.2021.669846
    [Google Scholar]
  8. Sherzai A.Z. Tagliati M. Park K. Pezeshkian S. Sherzai D. Sherzai D. Micronutrients and risk of Parkinson’s disease. Gerontol. Geriatr. Med. 2016 2 10.1177/2333721416644286 28138496
    [Google Scholar]
  9. Wu F. Xu K. Liu L. Zhang K. Xia L. Zhang M. Teng C. Tong H. He Y. Xue Y. Zhang H. Chen D. Hu A. Vitamin B12 enhances nerve repair and improves functional recovery after traumatic brain injury by inhibiting ER stress-induced neuron injury. Front. Pharmacol. 2019 10 APR 406 10.3389/fphar.2019.00406 31105562
    [Google Scholar]
  10. Kook S-Y. Lee K-M. Kim Y. Cha M-Y. Kang S. Baik S.H. Lee H. Park R. Mook-Jung I. High-dose of vitamin C supplementation reduces amyloid plaque burden and ameliorates pathological changes in the brain of 5XFAD mice. Cell Death Dis. 2014 5 2 e1083 10.1038/cddis.2014.26 24577081
    [Google Scholar]
  11. Paleologos M. Dimming R.G. Lazarus R. Cohort study of vitamin C intake and cognitive impairment. Am J Epidemiol. 1998 148 1 45 50 10.1093/oxfordjournals.aje.a009559.
    [Google Scholar]
  12. Dursun E. Alaylıoğlu M. Bilgiç B. Hanağası H. Lohmann E. Atasoy I.L. Candaş E. Araz Ö.S. Önal B. Gürvit H. Yılmazer S. Gezen-Ak D. Vitamin D deficiency might pose a greater risk for ApoEɛ4 non-carrier Alzheimer’s disease patients. Neurol. Sci. 2016 37 10 1633 1643 10.1007/s10072‑016‑2647‑1 27357856
    [Google Scholar]
  13. Hira S. Saleem U. Anwar F. Sohail M.F. Raza Z. Ahmad B. β-Carotene: A Natural compound improves cognitive impairment and oxidative stress in a mouse model of streptozotocin-induced Alzheimer’s disease. Biomolecules 2019 9 9 441 10.3390/biom9090441 31480727
    [Google Scholar]
  14. Takasaki J. Ono K. Yoshiike Y. Hirohata M. Ikeda T. Morinaga A. Takashima A. Yamada M. Vitamin A has anti-oligomerization effects on amyloid-β in vitro . J. Alzheimers Dis. 2011 27 2 271 280 10.3233/JAD‑2011‑110455 21811022
    [Google Scholar]
  15. Murakami K. Murata N. Ozawa Y. Kinoshita N. Irie K. Shirasawa T. Shimizu T. Vitamin C restores behavioral deficits and amyloid-β oligomerization without affecting plaque formation in a mouse model of Alzheimer’s disease. J. Alzheimers Dis. 2011 26 1 7 18 10.3233/JAD‑2011‑101971 21558647
    [Google Scholar]
  16. Zhao X. Zhang M. Li C. Jiang X. Su Y. Zhang Y. Benefits of vitamins in the treatment of Parkinson's disease. Oxid Med Cell Longev. 2019 2019 9426867 10.1155/2019/9426867
    [Google Scholar]
  17. Olajide O.J. Yawson E.O. Gbadamosi I.T. Arogundade T.T. Lambe E. Obasi K. Lawal I.T. Ibrahim A. Ogunrinola K.Y. Ascorbic acid ameliorates behavioural deficits and neuropathological alterations in rat model of Alzheimer’s disease. Environ. Toxicol. Pharmacol. 2017 50 200 211 10.1016/j.etap.2017.02.010 28192749
    [Google Scholar]
  18. Sil S. Ghosh T. Gupta P. Ghosh R. Kabir S.N. Roy A. Dual role of Vitamin C on the neuroinflammation mediated neurodegeneration and memory impairments in colchicine induced rat model of Alzheimer disease. J. Mol. Neurosci. 2016 60 4 421 435 10.1007/s12031‑016‑0817‑5 27665568
    [Google Scholar]
  19. Yamini P. Ray R.S. Chopra K. Vitamin D3 attenuates cognitive deficits and neuroinflammatory responses in ICV-STZ induced sporadic Alzheimer’s disease. Inflammopharmacology 2018 26 1 39 55 10.1007/s10787‑017‑0372‑x 28702935
    [Google Scholar]
  20. Briones T.L. Darwish H. Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. J. Neuroinflammation 2012 9 1 727 10.1186/1742‑2094‑9‑244 23098125
    [Google Scholar]
  21. Saad El-Din S. Rashed L. Medhat E. Emad Aboulhoda B. Desoky Badawy A. Mohammed ShamsEldeen A. Abdelgwad M. Active form of vitamin D analogue mitigates neurodegenerative changes in Alzheimer’s disease in rats by targeting Keap1/Nrf2 and MAPK-38p/ERK signaling pathways. Steroids 2020 156 108586 10.1016/j.steroids.2020.108586 31982424
    [Google Scholar]
  22. Ertilav E. Barcin N.E. Ozdem S. Comparison of serum free and bioavailable 25-Hydroxyvitamin D levels in Alzheimer’s disease and healthy control patients. Lab. Med. 2021 52 3 219 225 10.1093/labmed/lmaa066 32893866
    [Google Scholar]
  23. Ali A. Shah S.A. Zaman N. Uddin M.N. Khan W. Ali A. Riaz M. Kamil A. Vitamin D exerts neuroprotection via SIRT1/nrf-2/ NF-kB signaling pathways against D-galactose-induced memory impairment in adult mice. Neurochem. Int. 2021 142 104893 10.1016/j.neuint.2020.104893 33159979
    [Google Scholar]
  24. Gugliandolo A. Bramanti P. Mazzon E. Role of vitamin E in the treatment of Alzheimer's disease: Evidence from animal models. Int J Mol Sci. 2017 18 12 2504 10.3390/ijms18122504
    [Google Scholar]
  25. Baroni L. Bonetto C. Rizzo G. Bertola C. Caberlotto L. Bazzerla G. Association between cognitive impairment and Vitamin B12, folate, and homocysteine status in elderly adults: A retrospective study. J. Alzheimers Dis. 2019 70 2 443 453 10.3233/JAD‑190249 31177227
    [Google Scholar]
  26. Yu L. Chen Y. Wang W. Xiao Z. Hong Y. Multi-Vitamin B supplementation reverses hypoxia-induced tau hyperphosphorylation and improves memory function in adult mice. J. Alzheimers Dis. 2016 54 1 297 306 10.3233/JAD‑160329 27497480
    [Google Scholar]
  27. Huang J.K. Jarjour A.A. Nait Oumesmar B. Kerninon C. Williams A. Krezel W. Kagechika H. Bauer J. Zhao C. Evercooren A.B-V. Chambon P. ffrench-Constant C. Franklin R.J.M. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat. Neurosci. 2011 14 1 45 53 10.1038/nn.2702 21131950
    [Google Scholar]
  28. de Wilde M.C. Vellas B. Girault E. Yavuz A.C. Sijben J.W. Lower brain and blood nutrient status in Alzheimer's disease: Results from meta-analyses. Alzheimers Dement (N Y) 2017 3 3 416 431 10.1016/j.trci.2017.06.002
    [Google Scholar]
  29. Kurutas E.B. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: Current state. Nutr J. 2016 15 1 71 10.1186/s12937‑016‑0186‑5
    [Google Scholar]
  30. Bhatti A.B. Usman M. Ali F. Satti S.A. Vitamin supplementation as an adjuvant treatment for Alzheimer’s disease. J Clin Diagn Res 2016 10 8 OE07 11 10.7860/JCDR/2016/20273.8261
    [Google Scholar]
  31. Lopes Da Silva S. Vellas B. Elemans S. Luchsinger J. Kamphuis P. Yaffe K. Sijben J. Groenendijk M. Stijnen T. Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis. Alzheimers Dement 2014 10 4 485 502 10.1016/j.jalz.2013.05.1771
    [Google Scholar]
  32. Foy C. Passmore A. Young I. Lawson J. Plasma chain-breaking antioxidants in Alzheimer’s disease, vascular dementia and Parkinson’s disease. QJM 1999 92 1 39 45 10.1093/qjmed/92.1.39
    [Google Scholar]
  33. Lloret A. Esteve D. Monllor P. Cervera-Ferri A. Lloret A. The effectiveness of vitamin E treatment in Alzheimer's disease. Int J Mol Sci. 2019 20 4 879 10.3390/ijms20040879
    [Google Scholar]
  34. Zandi P.P. Anthony J.C. Khachaturian A.S. Stone S.V. Gustafson D. Tschanz J.T. Norton M.C. Welsh-Bohmer K.A. Breitner J.C.S. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache county study. Arch Neurol. 2004 61 1 82 8 10.1001/archneur.61.1.82.
    [Google Scholar]
  35. Yuan C. Fondell E. Ascherio A. Okereke O.I. Grodstein F. Hofman A. Willett W.C. Long-term intake of dietary carotenoids is positively associated with late-life subjective cognitive function in a prospective study in US women. J Nutr. 2020 150 7 1871 1879 10.1093/jn/nxaa087
    [Google Scholar]
  36. Refsum H. Ueland P. M. Clinical significance of pharmacological modulation of homocysteine metabolism. Trends Pharmacol Sci. 1990 11 10 411 6 10.1016/0165‑6147(90)90148‑2.
    [Google Scholar]
  37. Douaud G. Refsum H. de Jager C.A. Jacoby R. Nichols T.E. Smith S.M. Smith A.D. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc. Natl. Acad. Sci. USA 2013 110 23 9523 9528 10.1073/pnas.1301816110 23690582
    [Google Scholar]
  38. Kumar A. Palfrey H.A. Pathak R. Kadowitz P.J. Gettys T.W. Murthy S.N. The metabolism and significance of homocysteine in nutrition and health. Nutr Metab (Lond) 2017 14 78 10.1186/s12986‑017‑0233‑z
    [Google Scholar]
  39. Price B.R. Wilcock D.M. Weekman E.M. Hyperhomocysteinemia as a risk factor for vascular contributions to cognitive impairment and dementia. Front Aging Neurosci. 2018 10 350 10.3389/fnagi.2018.00350
    [Google Scholar]
  40. de Jager C.A. Oulhaj A. Jacoby R. Refsum H. Smith A.D. Cognitive and clinical outcomes of homocysteine‐lowering B‐vitamin treatment in mild cognitive impairment: A randomized controlled trial. Int. J. Geriatr. Psychiatry 2012 27 6 592 600 10.1002/gps.2758 21780182
    [Google Scholar]
  41. Durga J. Van Boxtel M.P.J. Schouten G. Kok F.J. Jolles J. Katan M.B. Verhoef P. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet 2007 369 9557 208 16 10.1016/S0140‑6736(07)60109‑3.
    [Google Scholar]
  42. Morris M. C. Schneider J. A. Tangney C. C. Thoughts on B-vitamins and dementia. J Alzheimers Dis. 2006 9 4 429 33 10.3233/JAD‑2006‑9409
    [Google Scholar]
  43. Ford A.H. Almeida O.P. Effect of homocysteine lowering treatment on cognitive function: A systematic review and meta-analysis of randomized controlled trials. J. Alzheimers Dis. 2012 29 1 133 149 10.3233/JAD‑2012‑111739 22232016
    [Google Scholar]
  44. Ford A.H. Almeida O.P. Effect of vitamin B supplementation on cognitive function in the elderly: A systematic review and meta-analysis. Drugs Aging. 2019 36 5 419 434 10.1007/s40266‑019‑00649‑w
    [Google Scholar]
  45. Wald D.S. Kasturiratne A. Simmonds M. Effect of folic acid, with or without other B vitamins, on cognitive decline: meta-analysis of randomized trials. Am. J. Med. 2010 123 6 522 527.e2 10.1016/j.amjmed.2010.01.017 20569758
    [Google Scholar]
  46. Sun Y. Lu C.J. Chien K.L. Chen S.T. Chen R.C. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer’s disease: A 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin. Ther. 2007 29 10 2204 2214 10.1016/j.clinthera.2007.10.012 18042476
    [Google Scholar]
  47. Aisen P.S. Schneider L.S. Sano M. Diaz-Arrastia R. van Dyck C.H. Weiner M.F. Bottiglieri T. Jin S. Stokes K.T. Thomas R.G. Thal L.J. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA 2008 300 15 1774 1783 10.1001/jama.300.15.1774 18854539
    [Google Scholar]
  48. Kwok T. Wu Y. Lee J. Lee R. Yung C.Y. Choi G. Lee V. Harrison J. Lam L. Mok V. A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients. Clin. Nutr. 2020 39 8 2399 2405 10.1016/j.clnu.2019.11.005 31787369
    [Google Scholar]
  49. Van Der Zwaluw N.L. Dhonukshe-Rutten R.A.M. Van Wijngaarden J.P. Brouwer-Brolsma E.M. Van De Rest O. In 't Veld PH. Enneman AW. van Dijk SC. Ham AC. Swart KM. van der Velde N. van Schoor NM. van der Cammen TJ. Uitterlinden AG. Lips P. Kessels RP. de Groot LC. Results of 2-year vitamin B treatment on cognitive performance: Secondary data from an RCT. Neurology. 2014 83 23 2158 66 10.1212/WNL.0000000000001050.
    [Google Scholar]
  50. Ulusu N.N. Yilmaz G. Erbayraktar Z. Evli̇ce A.T. Aras S. Yener G. Avci A. A Turkish 3-center study evaluation of serum folic acid and vitamin B12 levels in Alzheimer disease. Turk. J. Med. Sci. 2015 45 5 1159 1166 10.3906/sag‑1406‑136 26738362
    [Google Scholar]
  51. Lu'o'ng Kv. Nguyen LT. Role of thiamine in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2011 26 8 588 98 10.1177/1533317511432736
    [Google Scholar]
  52. Rafiee S. Asadollahi K. Riazi G. Ahmadian S. Saboury A.A. Vitamin B12 inhibits tau fibrillization via binding to cysteine residues of tau. ACS Chem. Neurosci. 2017 8 12 2676 2682 10.1021/acschemneuro.7b00230 28841372
    [Google Scholar]
  53. Lanyau-Domínguez Y. Macías-Matos C. Jesús J. María G. Suárez-Medina R. Eugenia M. Noriega-Fernández L. Guerra-Hernández M. Calvo-Rodríguez M. Sánchez-Gil Y. García-Klibanski M. Herrera-Javier D. Arocha-Oriol C. Díaz-Domínguez M. Levels of vitamins and homocysteine in older adults with Alzheimer disease or mild cognitive impairment in Cuba. MEDICC Rev. 2020 22 4 40 47 10.37757/MR2020.V22.N4.14 33295319
    [Google Scholar]
  54. Chen H. Liu S. Ji L. Wu T. Ji Y. Zhou Y. Zheng M. Zhang M. Xu W. Huang G. Folic acid supplementation mitigates Alzheimer’s disease by reducing inflammation: A Randomized controlled trial. Mediators Inflamm. 2016 2016 1 10 10.1155/2016/5912146 27340344
    [Google Scholar]
  55. Soh Y. Lee D.H. Won C.W. Association between Vitamin B12 levels and cognitive function in the elderly Korean population. Medicine (Baltimore) 2020 99 30 e21371 10.1097/MD.0000000000021371 32791746
    [Google Scholar]
  56. Dias V. Junn E. Mouradian M.M. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis. 2013 3 4 461 91 10.3233/JPD‑130230
    [Google Scholar]
  57. Huang Z. Liu Y. Qi G. Brand D. Zheng S.G. Role of Vitamin A in the immune system. J Clin Med. 2018 7 9 258 10.3390/jcm7090258
    [Google Scholar]
  58. Al Tanoury Z. Piskunov A. Rochette-Egly C. Vitamin A and retinoid signaling: Genomic and nongenomic effects. J Lipid Res. 2013 54 7 1761 75 10.1194/jlr.R030833
    [Google Scholar]
  59. Luong K.V.Q. Nguyễn L.T.H. The beneficial role of thiamine in Parkinson disease. CNS Neurosci Ther. 2013 19 7 461 8 10.1111/cns.12078
    [Google Scholar]
  60. Franco-Iborra S. Vila M. Perier C. Mitochondrial quality control in neurodegenerative diseases: Focus on Parkinson's disease and Huntington's disease. Front Neurosci. 2018 12 342 10.3389/fnins.2018.00342
    [Google Scholar]
  61. Marashly E.T. Bohlega S.A. Riboflavin has neuroprotective potential: Focus on Parkinson's disease and Migraine. Front Neurol. 2017 8 333 10.3389/fneur.2017.00333
    [Google Scholar]
  62. Shah S.A. Yoon G.H. Kim H.O. Kim M.O. Vitamin C neuroprotection against dose-dependent glutamate-induced neurodegeneration in the postnatal brain. Neurochem. Res. 2015 40 5 875 884 10.1007/s11064‑015‑1540‑2 25701025
    [Google Scholar]
  63. Park H.A. Ellis A.C. Dietary antioxidants and Parkinson's disease. Antioxidants (Basel). 2020 9 7 570 10.3390/antiox9070570
    [Google Scholar]
  64. McAllister C.J. Scowden E.B. Dewberry F.L. Richman A. Renal failure secondary to massive infusion of vitamin C. JAMA 1984 252 13 1684 10.1001/jama.1984.03350130016019 6471294
    [Google Scholar]
  65. Wong K. Thomson C. Bailey R.R. McDIARMID S. Gardner J. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust. N. Z. J. Med. 1994 24 4 410 411 10.1111/j.1445‑5994.1994.tb01477.x 7980244
    [Google Scholar]
  66. Grosso G. Bei R. Mistretta A. Marventano S. Calabrese G. Masuelli L. Giganti M.G. Modesti A. Galvano F. Gazzolo D. Effects of vitamin C on health: A review of evidence. Front Biosci (Landmark Ed). 2013 18 3 1017 29 10.2741/4160.
    [Google Scholar]
  67. Gold J. Shoaib A. Gorthy G. Grossberg G.T. The role of vitamin D in cognitive disorders in older adults. Europ. Neurol. Rev. 2018 14 1 41 46 10.17925/USN.2018.14.1.41
    [Google Scholar]
  68. Kunzler A. Ribeiro C.T. Gasparotto J. Petiz L.L. da Rosa Silva H.T. da Silva J.D. Jr Bortolin R. de Souza P.O. Barreto F. Espitia-Perez P. Schnorr C.E. Somensi N. Moreira J.C.F. Gelain D.P. The effects of retinol oral supplementation in 6-hydroxydopamine dopaminergic denervation model in Wistar rats. Neurochem. Int. 2019 125 25 34 10.1016/j.neuint.2019.02.002 30739037
    [Google Scholar]
  69. Prema A. Janakiraman U. Manivasagam T. Justin Thenmozhi A. Neuroprotective effect of lycopene against MPTP induced experimental Parkinson’s disease in mice. Neurosci. Lett. 2015 599 12 19 10.1016/j.neulet.2015.05.024 25980996
    [Google Scholar]
  70. Kaur H. Chauhan S. Sandhir R. Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson’s disease. Neurochem. Res. 2011 36 8 1435 1443 10.1007/s11064‑011‑0469‑3 21484267
    [Google Scholar]
  71. Tran H.H. Dang S.N.A. Nguyen T.T. Huynh A.M. Dao L.M. Kamei K. Yamaguchi M. Dang T.T.P. Drosophila ubiquitin c-terminal hydrolase knockdown model of Parkinson’s disease. Sci. Rep. 2018 8 1 4468 10.1038/s41598‑018‑22804‑w 29535397
    [Google Scholar]
  72. Man Anh H. Linh D.M. My Dung V. Thi Phuong Thao D. Evaluating dose- and time-dependent effects of vitamin c treatment on a Parkinson’s disease fly model. Parkinsons Dis. 2019 2019 1 14 10.1155/2019/9720546 30719278
    [Google Scholar]
  73. Lima L.A.R. Lopes M.J.P. Costa R.O. Lima F.A.V. Neves K.R.T. Calou I.B.F. Andrade G.M. Viana G.S.B. Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats. J. Neuroinflammation 2018 15 1 249 10.1186/s12974‑018‑1266‑6 30170624
    [Google Scholar]
  74. Schirinzi T. Martella G. Imbriani P. Di Lazzaro G. Franco D. Colona V.L. Alwardat M. Sinibaldi Salimei P. Mercuri N.B. Pierantozzi M. Pisani A. Dietary Vitamin E as a protective factor for Parkinson’s disease: Clinical and experimental evidence. Front. Neurol. 2019 10 148 10.3389/fneur.2019.00148 30863359
    [Google Scholar]
  75. Ueda S. Sakakibara S. Nakadate K. Noda T. Shinoda M. Joyce J.N. Degeneration of dopaminergic neurons in the substantia nigra of zitter mutant rat and protection by chronic intake of Vitamin E. Neurosci. Lett. 2005 380 3 252 256 10.1016/j.neulet.2005.01.053 15862896
    [Google Scholar]
  76. Lud Cadet J. Katz M. Jackson-Lewis V. Fahn S. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence. Brain Res. 1989 476 1 10 10.1016/0006‑8993(89)91530‑8.
    [Google Scholar]
  77. Roghani M. Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: Behavioral and histochemical evidence. Brain Res. 2001 892 1 211 217 10.1016/S0006‑8993(00)03296‑0 11172767
    [Google Scholar]
  78. Heim C. Kolasiewicz W. Kurz T. Sontag K.H. Behavioral alterations after unilateral 6-hydroxydopamine lesions of the striatum. Effect of alpha-tocopherol. Pol. J. Pharmacol. 2001 53 5 435 448 11990061
    [Google Scholar]
  79. Craft N.E. Haitema T.B. Garnett K.M. Fitch K.A. Dorey C.K. Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J. Nutr. Health Aging 2004 8 3 156 162 15129301
    [Google Scholar]
  80. Ying A.F. Khan S. Wu Y. Jin A. Wong A.S.Y. Tan E.K. Yuan J.M. Koh W.P. Tan L.C.S. Dietary antioxidants and risk of Parkinson’s disease in the Singapore Chinese health study. Mov. Disord. 2020 35 10 1765 1773 10.1002/mds.28173 32643256
    [Google Scholar]
  81. Dietiker C. Kim S. Zhang Y. Christine C. W. Characterization of Vitamin B12 supplementation and correlation with clinical outcomes in a large longitudinal study of early Parkinson's disease. J Mov Disord. 2019 12 2 91 96 10.14802/jmd.18049
    [Google Scholar]
  82. Shen L. Associations between B vitamins and Parkinson’s disease. Nutrients 2015 7 9 7197 7208 10.3390/nu7095333 26343714
    [Google Scholar]
  83. Drouin G. Godin J-R. Pagé B. The genetics of vitamin C loss in vertebrates. Curr Genomics. 2011 12 5 371 8 10.2174/138920211796429736.
    [Google Scholar]
  84. Håglin L. Johansson I. Forsgren L. Bäckman L. Intake of vitamin B before onset of Parkinson’s disease and atypical parkinsonism and olfactory function at the time of diagnosis. Eur. J. Clin. Nutr. 2017 71 1 97 102 10.1038/ejcn.2016.181 27703161
    [Google Scholar]
  85. Nagayama H. Hamamoto M. Ueda M. Nito C. Yamaguchi H. Katayama Y. The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol. 2004 27 6 270 3 10.1097/01.wnf.0000150865.21759.bc
    [Google Scholar]
  86. Ozturk E. A. Gundogdu I. Tonuk B. Kocer B. G. Tombak Y. Comoglu S. Cakci A. Bone mass and vitamin D levels in Parkinson’s disease: Is there any difference between genders? J Phys Ther Sci. 2016 28 8 2204 9 10.1589/jpts.28.2204
    [Google Scholar]
  87. Sunyecz J. The use of calcium and vitamin D in the management of osteoporosis. Ther. Clin. Risk Manag. 2008 4 4 827 836 10.2147/TCRM.S3552 19209265
    [Google Scholar]
  88. Luo X. Ou R. Dutta R. Tian Y. Xiong H. Shang H. Association between serum Vitamin D levels and Parkinson’s disease: A systematic review and meta-analysis. Front. Neurol. 2018 9 NOV 909 10.3389/fneur.2018.00909 30483205
    [Google Scholar]
  89. Luthra N.S. Kim S. Zhang Y. Christine C.W. Characterization of vitamin D supplementation and clinical outcomes in a large cohort of early Parkinson’s disease. J. Clin. Mov. Disord. 2018 5 1 7 10.1186/s40734‑018‑0074‑6 30397507
    [Google Scholar]
  90. Vatassery G.T. Fahn S. Kuskowski M.A. Alpha tocopherol in CSF of subjects taking high‐dose vitamin E in the DATATOP study. Neurology 1998 50 6 1900 1902 10.1212/WNL.50.6.1900 9633757
    [Google Scholar]
  91. Pham D.Q. Plakogiannis R. Vitamin E supplementation in Alzheimer’s disease, Parkinson’s disease, tardive dyskinesia, and cataract: Part 2. Ann. Pharmacother. 2005 39 12 2065 2072 10.1345/aph.1G271 16288072
    [Google Scholar]
  92. Conrad G.D. Is Ginkgo biloba and/or a Multivitamin-multimineral supplement a therapeutic option for Parkinson’s disease? A case report. Glob. Adv. Health Med. 2014 3 4 43 44 10.7453/gahmj.2013.096 25105077
    [Google Scholar]
  93. Sidhu A. Diwan V. Kaur H. Bhateja D. Singh C.K. Sharma S. Padi S.S.V. Nicotinamide reverses behavioral impairments and provides neuroprotection in 3˗nitropropionic acid induced animal model ofHuntington’s disease: Implication of oxidative stress˗ poly(ADP˗ ribose) polymerase pathway. Metab. Brain Dis. 2018 33 6 1911 1921 10.1007/s11011‑018‑0297‑0 30054774
    [Google Scholar]
  94. Fort Molnár M. Török R. Szalárdy L. Sümegi E. Vécsei L. Klivényi P. High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice. Acta Neurobiol Exp (Wars) 2016 76 3 176 81 10.21307/ane‑2017‑017.
    [Google Scholar]
  95. Kašparová S. Sumbalová Z. Bystrický P. Kucharská J. Liptaj T. Mlynárik V. Gvozdjáková A. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington’s disease. Neurochem. Int. 2006 48 2 93 99 10.1016/j.neuint.2005.09.002 16290265
    [Google Scholar]
  96. Peyser C.E. Folstein M. Chase G.A. Starkstein S. Brandt J. Cockrell J.R. Bylsma F. Coyle J.T. McHugh P.R. Folstein S.E. Trial of d-alpha-tocopherol in Huntington’s disease. Am. J. Psychiatry 1995 152 12 1771 1775 10.1176/ajp.152.12.1771 8526244
    [Google Scholar]
  97. Babri S. Mehrvash F. Mohaddes G. Hatami H. Mirzaie F. Effect of intrahippocampal administration of vitamin C and progesterone on learning in a model of multiple sclerosis in rats. Adv. Pharm. Bull. 2015 5 1 83 87 10.5681/apb.2015.011 25789223
    [Google Scholar]
  98. Adzemovic M.Z. Zeitelhofer M. Hochmeister S. Gustafsson S.A. Jagodic M. Efficacy of vitamin D in treating multiple sclerosis-like neuroinflammation depends on developmental stage. Exp. Neurol. 2013 249 39 48 10.1016/j.expneurol.2013.08.002 23954214
    [Google Scholar]
  99. Miller E.D. Dziedzic A. Saluk-Bijak J. Bijak M. A review of various antioxidant compounds and their potential utility as complementary therapy in multiple sclerosis. Nutrients. 2019 11 7 1528 10.3390/nu11071528
    [Google Scholar]
  100. Sintzel M.B. Rametta M. Reder A.T. Vitamin D and multiple sclerosis: A comprehensive review. Neurol Ther. 2018 7 1 59 85 10.1007/s40120‑017‑0086‑4
    [Google Scholar]
  101. Torkildsen Ø. Løken-Amsrud K.I. Wergeland S. Myhr K.M. Holmøy T. Fat-soluble vitamins as disease modulators in multiple sclerosis. Acta Neurol. Scand. 2013 127 196 16 23 10.1111/ane.12045 23190287
    [Google Scholar]
  102. Runia T.F. Hop W.C.J. de Rijke Y.B. Hintzen R.Q. Vitamin A is not associated with exacerbations in multiple sclerosis. Mult. Scler. Relat. Disord. 2014 3 1 34 39 10.1016/j.msard.2013.06.011 25877971
    [Google Scholar]
  103. Najafi M.R. Shaygannajad V. Mirpourian M. Gholamrezaei A. Vitamin B(12) deficiency and multiple sclerosis; Is there any association? Int. J. Prev. Med. 2012 3 4 286 289 22624086
    [Google Scholar]
  104. Costantini A. Nappo A. Pala M.I. Zappone A. High dose thiamine improves fatigue in multiple sclerosis. BMJ Case Rep. 2013 2013 bcr2013009144 10.1136/bcr‑2013‑009144 23861280
    [Google Scholar]
  105. Besler H.T. Omoǧlu S. Oku Z. Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr Neurosci. 2002 5 3 215 20 10.1080/10284150290029205
    [Google Scholar]
  106. Polachini C.R.N. Spanevello R.M. Zanini D. Baldissarelli J. Pereira L.B. Schetinger M.R.C. da Cruz I.B.M. Assmann C.E. Bagatini M.D. Morsch V.M. Evaluation of delta-aminolevulinic dehydratase activity, oxidative stress biomarkers, and vitamin D levels in patients with multiple sclerosis. Neurotox. Res. 2016 29 2 230 242 10.1007/s12640‑015‑9584‑2 26690779
    [Google Scholar]
  107. Tavazzi B. Batocchi A.P. Amorini A.M. Nociti V. D’Urso S. Longo S. Gullotta S. Picardi M. Lazzarino G. Serum metabolic profile in multiple sclerosis patients. Mult. Scler. Int. 2011 2011 1 8 10.1155/2011/167156 22096628
    [Google Scholar]
  108. Munger K.L. Åivo J. Hongell K. Soilu-Hänninen M. Surcel H.M. Ascherio A. Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish Maternity Cohort. JAMA Neurol. 2016 73 5 515 519 10.1001/jamaneurol.2015.4800 26953778
    [Google Scholar]
  109. Smolders J. Damoiseaux J. Menheere P. Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, A review. J Neuroimmunol. 2008 194 1-2 7 17 10.1016/j.jneuroim.2007.11.014
    [Google Scholar]
  110. Müller T. Lohse L. Blodau A. Frommholz K. Vitamin D rise enhances blood perfusion in patients with multiple sclerosis. J. Neural Transm. (Vienna) 2019 126 12 1631 1636 10.1007/s00702‑019‑02093‑x 31620863
    [Google Scholar]
  111. Hernández-Pedro N.Y. Espinosa-Ramirez G. De La Cruz V.P. Pineda B. Sotelo J. Initial immunopathogenesis of multiple sclerosis: Innate immune response. Clin Dev Immunol. 2013 2013 413465 10.1155/2013/413465
    [Google Scholar]
  112. Long Kv. Nguyễn LT. Roles of vitamin D in amyotrophic lateral sclerosis: Possible genetic and cellular signaling mechanisms. Mol Brain. 2013 6 16 10.1186/1756‑6606‑6‑16.
    [Google Scholar]
  113. Cortese R. D'Errico E. Introna A. Schirosi G. Scarafino A. Distaso E. Simone I. Vitamin D levels in serum of amyotrophic lateral sclerosis patients. Neurology 2015 10.1212/WNL.84.14_supplement.P2.069.
    [Google Scholar]
  114. Camu W. Tremblier B. Plassot C. Alphandery S. Salsac C. Pageot N. Juntas-Morales R. Scamps F. Daures J.P. Raoul C. Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiol. Aging 2014 35 5 1198 1205 10.1016/j.neurobiolaging.2013.11.005 24378089
    [Google Scholar]
  115. Gianforcaro A. Solomon J.A. Hamadeh M.J. Vitamin D(3) at 50x AI attenuates the decline in paw grip endurance, but not disease outcomes, in the G93A mouse model of ALS, and is toxic in females. PLoS One 2013 8 2 e30243 10.1371/journal.pone.0030243 23405058
    [Google Scholar]
  116. Gianforcaro A. Hamadeh M.J. Dietary vitamin D3 supplementation at 10× the adequate intake improves functional capacity in the G93A transgenic mouse model of ALS, a pilot study. CNS Neurosci. Ther. 2012 18 7 547 557 10.1111/j.1755‑5949.2012.00316.x 22591278
    [Google Scholar]
  117. Solomon J.A. Gianforcaro A. Hamadeh M.J. Vitamin D3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis. PLoS One 2011 6 12 e29354 10.1371/journal.pone.0029354 22216257
    [Google Scholar]
  118. Libonati L. Onesti E. Gori M.C. Ceccanti M. Cambieri C. Fabbri A. Frasca V. Inghilleri M. Vitamin D in amyotrophic lateral sclerosis. Funct. Neurol. 2017 32 1 35 40 10.11138/FNeur/2017.32.1.035 28380322
    [Google Scholar]
  119. Ascherio A. Weisskopf M.G. O’Reilly E.J. Jacobs E.J. McCullough M.L. Calle E.E. Cudkowicz M. Thun M.J. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann. Neurol. 2005 57 1 104 110 10.1002/ana.20316 15529299
    [Google Scholar]
  120. Chiricosta L. Gugliandolo A. Tardiolo G. Bramanti P. Mazzon E. Transcriptomic analysis of mapk signaling in NSC-34 motor neurons treated with Vitamin E. Nutrients 2019 11 5 1081 10.3390/nu11051081 31096690
    [Google Scholar]
/content/journals/cn/10.2174/011570159X327677240902105443
Loading
Exploration of the Role of Vitamins in Preventing Neurodegenerative Diseases: Comprehensive Review on Preclinical and Clinical Findings
Bentham Science Publishers ; https://doi.org/10.2174/011570159X327677240902105443
/content/journals/cn/10.2174/011570159X327677240902105443
/content/journals/cn/10.2174/011570159X327677240902105443
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: prevention ; Alzheimer's disease ; Parkinson's disease ; vitamin ; Huntington's disease ; multiple sclerosis ; amyotrophic lateral sclerosis ; Neurodegenerative diseases

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test